Axicabtagene Ciloleucel for Adults With Relapsed or Refractory Large B-cell Lymphoma


( Last Updated : August 15, 2019)
Project Line:
Health Technology Review
Project Sub Line:
Optimal Use
Project Number:
CT0002-000

Details


Final Biosimilar Summary Dossier Issued:

Axicabtagene ciloleucel is a chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. This includes diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and subtypes of DLBCL (e.g., primary mediastinal large B-cell lymphoma and DLBCL arising from follicular lymphoma).

CADTH completed a review of manufacturer-submitted materials and published literature to assess the clinical impact, cost-effectiveness, implementation considerations (including patient and caregiver perspectives and experiences, and other factors such as facilities, eligibility, travel, and resource costs), and ethical considerations associated with the provision of axicabtagene ciloleucel therapy in Canada.

The project includes the following key components:

  • protocols
  • clinical systematic review
  • economic review
  • review of implementation considerations, ethics, and patient and caregiver perspectives and experiences
  • recommendations report.

Read more about CAR T-cell therapy reviews at CADTH.


Files

Axicabtagene Ciloleucel for Large B-Cell Lymphoma

Optimal Use Report
In Brief
PUBLISHED: August 15, 2019

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Recommendations

Optimal Use Report
Recommendation Report
PUBLISHED: August 15, 2019

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Clinical Report

Optimal Use Report
Clinical Report
PUBLISHED: August 15, 2019

Axicabtagene Ciloleucel for Diffuse Large B-Cell Lymphoma: Economic Review Report

Optimal Use Report
Economic Review Report
PUBLISHED: August 15, 2019

Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Ethics and Implementation Report

Optimal Use Report
Ethics and Implementation Report
PUBLISHED: August 15, 2019

Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma: Implementation and Ethics Project Protocol

Optimal Use Report
Implementation and Ethics Protocol
PUBLISHED: January 30, 2019

Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma: Implementation and Ethics Project Protocol

Optimal Use Report
Implementation and Ethics Protocol Amendment
PUBLISHED: May 21, 2019